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Abstract
The COVID-19 pandemic has unleashed a deluge of publications. For this cross-sectional
study we compared the amount and reporting characteristics of COVID-19-related aca-
demic articles and preprints and the number of ongoing clinical trials and systematic
reviews. To do this, we searched the PubMed database of citations and abstracts for pub-
lished life science journals by using appropriate combinations of medical subject headings
(MeSH terms), and the COVID-19 section of the MedRxiv and BioRxiv archives up to 20
May 2020 (21 weeks). In addition, we searched Clinicaltrial.gov, Chinese Clinical Trial Reg-
istry, EU Clinical Trials Register, and 15 other trial registers, as well as PROSPERO, the
international prospective register of systematic reviews. The characteristics of each publica-
tion were extracted. Regression analyses and Z tests were used to detect publication trends
and their relative proportions. A total of 3635 academic publications and 3805 preprints
were retrieved. Only 8.6% (n = 329) of the preprints were already published in indexed jour-
nals. The number of academic and preprint publications increased significantly over time
(p<0.001). Case reports (6% academic vs 0.9% preprints; p<0.001) and letters (17.4% aca-
demic vs 0.5% preprints; p<0.001) accounted for a greater share of academic compared to
preprint publications. Differently, randomized controlled trials (0.22% vs 0.63%; p<0.001)
and systematic reviews (0.08% vs 5%) made up a greater share of the preprints. The rela-
tive proportion of clinical studies registered at Clinicaltrials.gov, Chinese Clinical Trial Regis-
try, and EU Clinical Trials Register was 57.9%, 49.5%, and 98.9%, respectively, most of
which were still “recruiting”. PROSPERO listed 962 systematic review protocols. Preprints
were slightly more prevalent than academic articles but both were increasing in number.
The void left by the lack of primary studies was filled by an outpour of immediate opinions
(i.e., letters to the editor) published in PubMed-indexed journals. Summarizing, preprints
have gained traction as a publishing response to the demand for prompt access to empirical,
albeit not peer-reviewed, findings during the present pandemic.
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Introduction
The pandemic spread of a novel human coronavirus, termed severe acute respiratory syn-
drome coronavirus 2 (SARS-CoV-2) by the International Committee on Taxonomy of Viruses
[1] since late 2019 [2], has created a global health emergency. The urgent need to keep the pub-
lic health response to COVID-19 informed by near-real-time monitoring and assessment [3]
has brought with it the expansion of scientific effort and the production of new knowledge at
an unprecedented rate [4]. There has been a parallel surge in the research being conducted,
posted, and shared in the print and the digital media [5, 6]. The research progress in any area
can be quantitatively estimated by bibliometric and scientometric analysis of publications that
provides a comprehensive overview of trends in scientific research. Such analyses have been
widely used for mapping scientific knowledge in diverse disciplines [7, 8]. For example, to bet-
ter organize emerging and rapidly scientific developments, scoping reviews coupled with bib-
liometric and scientometric analysis have documented the networks of contributing authors,
institutions, and countries [4, 6, 9, 10]. However, no reviews to date have focused on the epide-
miology and the reporting characteristics of publications related to the COVID-19 pandemic
[11, 12] or the advances in research during the pandemic [13–15].
Scientific information is distributed through various print and digital channels, among
which are the formal publication sources such as registers of primary studies (i.e., trials) and
systematic reviews, preprints, and academic publications. A clinical trials registry is a platform
in which clinical trials are registered and cataloged. Clinical trials play an important role in
response to the COVID-19 pandemic as a means to translate evidence from basic research into
clinical practice [16, 17]. A systematic review protocol registry is an international database in
which prospective systematic reviews in health and social care are listed. Systematic reviews
should be registered at inception (at the protocol stage) to help avoid outcome reporting
biases, publication bias, unplanned duplication and waste of resources, especially during the
present global health emergency [18, 19]. Preprints are preliminary reports of work and have
not yet undergone peer review. As such, they should not be relied on to guide clinical practice
or health-related behavior and should not be reported in the news media as established infor-
mation [20]. Preprint servers are open access online repositories that house preprint research
articles by authors who choose to make their research immediately and freely available to the
public. Research articles can receive commentary and peer review prior to journal submission,
thus accelerating the dissemination of scientific findings [21, 22]. Preprints posted during the
Ebola and Zika outbreaks divulged novel analyses and new data, while many of those that later
appeared in academic publications were available for more than 100 days before publication
[21]. Many preprints never undergo peer review; for instance, less than 5% of journal articles
about the Ebola and the Zika virus were posted as preprints prior to publication in journals
[21]. The information in preprints lacks the scrutiny and validity of an external, scientific
review [23]. Nevertheless, analysis of preprints and ongoing investigations (trials and reviews)
is essential for scientific advancement where timeliness is key, though peer reviews are still
expedited for new relevant research.
With this context in mind, we wanted to take a snapshot of the amount of scientific devel-
opment devoted to COVID-19 and gain an idea of the current status of global research. We
also thought it necessary to obtain an insight into the reporting of future research, its amount,
design, publication venues, and characteristics. To do this, we:
1. Compared the amount of COVID-19 related research in academic publications and pre-
prints (not peer reviewed) stratified by key characteristics: species (Humans, Animals),
study design (e.g., systematic review, randomized controlled trials—RCTs), and research
area (e.g., drug treatment)
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Abbreviations: COVID-19, Coronavirus disease 19;
SARS-CoV-2, Severe Acute Respiratory Syndrome
coronavirus 2; PROSPERO, international
prospective register of systematic reviews; MeSH,
Medical Subject Headings; RCTs, randomized
controlled trials.
2. Evaluated the amount and key characteristics (e.g., research area) of ongoing COVID-19
research contained in clinical trials registers and systematic reviews.
Methods
For this cross-sectional study, COVID-19 related-publications listed in electronic databases as
of 20 May 2020 were reviewed.
Data sources
We searched the PubMed database for COVID-19-related academic publications through its
indexation system. PubMed is a comprehensive database that comprises more than 30 million
citations (as of May 2020) for biomedical literature from MEDLINE, life science journals, and
online books [24]. There is evidence in the health field that adding databases other than
PubMed has only modest impact on the results of systematic reviews [25]. The medical subject
headings (MeSH terms) in PubMed are organized in a hierarchical tree and assigned to each
paper by subject-specialist indexers. For searching COVID-19-related articles, we used the sup-
plementary concept records (SCRs). MEDLINE indexers regularly come across substances in
the literature that are not currently MeSH headings. When this happens, the National Library of
Medicine staff adds these substances to the MeSH vocabulary as SCRs. While MeSH headings
are updated annually, new SCRs are added weekly. Therefore, COVID-19 articles are systemi-
cally indexed by research topic regardless of the specific words used by the authors. We con-
ducted target searches in PubMed that included the use of appropriate combinations of MeSH
terms and SCRs related to COVID-19 and related terms (e.g., SARS-CoV-2, coronavirus dis-
ease), filtered by species, research design, and research area (S1 Appendix. PubMed database).
We searched two popular sources for COVID-19-related preprints [26], the MedRxiv and
BioRxiv databases, here defined as proxy indicators of published empirical not yet peer-
reviewed literature. Articles on these preprints servers are examined by in-house staff who
check for such issues as plagiarism and incompleteness [27] (S1 Appendix. Preprints MedR-
xiv and BioRxiv databases).
We then investigated all primary registries that meet the International Committee of Medi-
cal Journal Editors (ICMJE) criteria according to the WHO Registry Network. Primary regis-
tries in the WHO Registry Network meet specific criteria for content, quality, and validity,
accessibility, unique identification, technical capacity and administration [28]. Additionally,
we searched the PROSPERO international prospective register of systematic reviews database
(S1 Appendix. Primary register and PROSPERO register).
All searches were run on 20 May 2020 (covering a 21-week period), without language
restrictions.
Data extraction
Data records retrieved from PubMed, MedRxiv, BioRxiv, trials registers, and PROSPERO
databases were imported to Excel for further grouping and analysis. Data extraction was per-
formed by one author and then checked by the second author. Any uncertainties were dis-
cussed between the data extractors.
For academic publications and preprints, we extracted the bibliometric data and then ana-
lyzed and summarized the subsets of the study or reporting characteristics: species (Humans,
Animals); publication type (any type of article, systematic review, RCTs, epidemiologic studies,
Letter to the Editor with or without original data); the distribution by research area (e.g., vac-
cine, drug treatment, rehabilitation, diagnostic testing, measures for infection prevention and
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control including social distance, masks); and biology according to the indexation facilities
and the respective search tags or filters. Since the preprint servers have no such filters/tags, we
manually extracted and coded the topics. Study designs such as laboratory experiments (e.g.,
genomics) and prognostic models were included in the epidemiology studies.
For the registers listing clinical trials, the following characteristics were filtered/tagged and
extracted: country, study type, phase, recruiting status. Species and research area/tag were
extracted from the records retrieved from the PROSPERO database.
Data analysis
Descriptive statistics were initially used for analysis. The total number of publications for each
data element (e.g., publication type), percentages, and frequencies were computed and dis-
played in tabular format, paired by academic and preprint sources. The total number of publi-
cations over time (weekly) was plotted onto a run chart. Simple linear regression with analysis
of variance (ANOVA) was applied to analyze the growth in the number of COVID-19-related
publications over time. Finally, two tailed two-sample Z-tests were performed to determine
whether the proportion of each characteristic of the academic journal articles (indexed in
PubMed) differed significantly from those contained in the preprint sources. Statistical signifi-
cance was set at<0.05. Data analysis was performed using Stata Statistical Software. Release
16. (StataCorp LP, College Station, TX, USA).
Results
1. Amount and characteristics of COVID-19-related research reported in
academic and preprint (not peer reviewed) publications
From December 2019 through May 2020, a total of 7440 COVID-19-related publications were
retrieved: 3635 (48.9%) academic publications and 3805 (51.1%) preprints. Fig 1 presents the
number of academic and preprint publications by week from December 2019 through May
Fig 1. Linear regression over time for academic and preprint publications. Dates: 10 January 2020—first genomic data of its
etiological agent (SARS-CoV-2); 20 January 2020—reports of confirmed cases from three countries outside China; 24 January 2020—
first European case; 30 January 2020 –the WHO declares the novel coronavirus outbreak (2019-nCoV) a Public Health Emergency of
International Concern (PHEIC); 11 March 2020 –the WHO declares a status of pandemic; 25 March 2020 –cases confirmed in all
European Union/European Economic Area (EU/EEA) countries and in more than 150 countries worldwide.
https://doi.org/10.1371/journal.pone.0240123.g001
PLOS ONE Characteristics of COVID-19 publications, preprints, and registered clinical trials
PLOS ONE | https://doi.org/10.1371/journal.pone.0240123 October 6, 2020 4 / 15
2020. The increase in the number of academic and preprint publications was statistically sig-
nificant for both types (academic p<0.001, r2 = 0.8239; preprints p<0.001, r2 = 0.9133). Figs 2
and 3 present the absolute and the relative frequency of publications by week. Fig 4 presents
the trend of the ratio between the relative frequency of academic and preprint publications by
week. There was no statistically significant difference in the rate of weekly increase in relative
frequency between the two groups (p = 0.2388, r2 = 0.0856).
Table 1 presents the reporting characteristics of academic and preprint COVID-19-related
publications. In both types of publications, human subjects were predominant; the most men-
tioned research areas were prevention and control (26.1%, 950/3635 academic vs 42.4%, 1615/
3805 preprints; p<0.001) and diagnosis (21.5%, 781/3635 academic vs 25.3%, 962/3805 pre-
prints; p<0.001).
There were statistically significant differences in the relative frequency of study types
between academic and preprint publications. For instance, RCTs were significantly more fre-
quently reported in preprints than in academic publications (academic 0.2%, 8/3635 vs. preprints
0.6%, 24/3805; p<0.001). Similarly, systematic reviews appeared significantly more often in pre-
prints (academic 0.8%, 29/3635 vs. preprints 5.0%, 193/3805; p<0.001). Observational studies
were significantly more common in preprint than in academic publications (academic 0.6%, 21/
3635 vs. preprints 24.7%, 940/3805; p<0.001). In contrast, case reports and letters to the editor
were significantly more common in academic publications (case reports in academic publications
6.0%, 219/3635 vs. preprints 0.9%, 35/3805; p<0.001; letters to the editor in academic publications
17.4%, 632/3635 vs. preprints 0.5%, 19/3805; p<0.001). Overall, in both types of publications the
most often mentioned research areas were prevention and control (26.1%, 950/3635 vs. 42.4%,
1615/3805; p<0.001) and diagnosis (21.5%, 781/3635 vs. 25.3%, 962/3805).
Only 8.6% (329/3805) of preprints appeared in academic journals (as of May 2020), with a
median of 28 days (interquartile range [IQR] 14–52; min–max: 0–117) from preprint posting
Fig 2. Absolute frequency of academic and preprint publications by week.
https://doi.org/10.1371/journal.pone.0240123.g002
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to publication online. Observational studies (87.8%, n = 289/329) and RCTs (5.6%, n = 18/
329) were most often published, while prevention and control (40.7%, n = 134/329) and diag-
nosis (31.6%, n = 104/329) were the most frequently mentioned research areas.
2. Characteristics of ongoing COVID-19-related research in the registers
(trials and systematic reviews)
Table 2 shows that 1621/339,863 (0.5%) records in Clinicaltrials.gov were COVID-19-related
and that 652/32553 (2%) records in the Chinese Clinical Trial Registry (ChiCTR) were
COVID-19-related. No other register had over 200 records of COVID-19-related research.
Fig 3. Relative distribution of academic and preprint publications by week.
https://doi.org/10.1371/journal.pone.0240123.g003
Fig 4. Linear regression of ratios between relative frequency (academic/preprint publications) by week.
https://doi.org/10.1371/journal.pone.0240123.g004
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Table 3 presents the characteristics of the two primary registries with the highest number
of COVID-19-related research studies. The most frequent study types were interventional
studies in Clinicaltrials.gov and in ChiCTR (60% and 50%, respectively), with phase 3 the most
frequent in Clinicaltrials.gov (15%). The most frequent recruiting status was “ongoing” in all
registers (min-max: 47%-99%).
Table 4 presents the characteristics of the records retrieved from the PROSPERO database
for COVID-19-related systematic reviews: 962 systematic reviews were registered; almost all
focused on humans (99.7%); the two most frequent research areas were treatment (19.1%) and
health impact (16.6%).
Discussion
During the first half of 2020 (about 5 months/21 weeks), the spread of COVID-19 matched the
rapid and statistically significant increase in the number of publications appearing in academic
journals and on preprint servers (3805 and 3635 records, respectively; p< 0.001). Clinicians,
Table 1. Characteristics of COVID-19-related academic (PubMed) and preprint publications.
Characteristic PubMed N = 3635 No.
(%)
Preprints N = 3805 No.
(%)
Z value % Difference P value
Species Humans 3507 (96.5) 3634 (95.5) 2.14 1.0 <0.05
Animals 128 (3.5) 93 (2.4) 2.74 1.1 <0.05
Publication type Systematic review and/or meta-analysis 29 (0.8) 193 (5.0) -10.83 -4.2 <
0.0001
Randomized controlled trial 8 (0.2) 24 (0.6) -2.71 -0.4 <0.05
Phase I 1 0 1.02 1.0 >0.05
Phase II 3 3 0.06 0.0 >0.05
Phase III 0 2 -1.38 -2.0 >0.05
Phase IV 0 3 -1.69 -3.0 >0.05
Protocols 0 4 -1.96 -4.0 >0.05
Epidemiologic studies 222 (6.1) 3522 (92.6) -74.55 -86.5 <
0.0001
Observational studies 21 (0.6) 940 (24.7) -31.02 -24.1 <
0.0001
Case report 219 (6.0) 35 (0.9) 12.12 5.1 <
0.0001




Vaccine 101 (2.8) 114 (2.9) -0.56 -0.1 >0.05
Drug therapy 57 (1.6) 325 (8.5) -13.62 -6.9 <
0.0001
Diagnosis 781 (21.5) 962 (25.3) -3.87 -3.8 <
0.0001
Prevention and control (e.g., masks, social
distancing)
950 (26.1) 1615 (42.4) -14.80 -16.3 <
0.0001
Rehabilitation (e.g., pulmonary rehabilitation) 23 (0.6) 5 (0.1) 3.53 0.5 <
0.0001
Prognosis 123 (3.4) 844 (22.2) -24.10 -18.8 <
0.0001
Biology/Genetic 43 (1.1) 866 (22.8) -28.41 -21.7 <
0.0001
Note: the sum of the characteristics does not correspond to the total number of publications since specifications or other may overlap.
https://doi.org/10.1371/journal.pone.0240123.t001
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researchers, public health authorities, and other stakeholders (e.g., government administra-
tors) need to be able to identify in a timely manner accurate and reliable health information
from trustworthy data sources. With this study we analyzed the frequency and type of publica-
tion covering the initial scientific response to the COVID-19 pandemic as of 20 May 2020. In
general, we noted that to fill the void left by the absence of primary studies, academic journals
ran opinion pieces (i.e., letters, editorials, commentary), whereas preprint servers listed empir-
ical studies, including epidemiological findings and research results in biology, infection diag-
nosis and prevention.
Our findings reflect the progressive advances in attempts to answer questions from the sci-
entific community. While the total number of publications rose dramatically in the first
months of the study period (not counting the last few weeks because of indexation delays), aca-
demic sources provided scarce higher-hierarchy evidence in the form of systematic reviews/
meta-analysis (n = 29) or randomized controlled trials (n = 8). This observation is shared by
previous studies that found few high-quality studies on COVID-19 [17, 29, 30]. Since there has
been insufficient time to design, approve, conduct, and conclude such studies, reports of pre-
liminary results can be expected over the upcoming months. A previous cross-sectional study
on COVID-19-related publications revealed that only a quarter of the first 2118 articles con-
tained original data [31]. In our study, the number of registered trial protocols listed as “ongo-
ing” in Clinicaltrials.gov and in ChiCTR (n = 795 and n = 308, respectively) signals an upward
trend. We retrieved a total of 2273 trials from the two registers and noted a phenomenal
growth rate in both. As of 22 February 2020, merely 171 COVID-19-related interventional tri-
als were registered (138 in ChiCTR and 33 in ClinicalTrials.gov) [32]; one month later (24
March 2020) the number was 614 COVID-19-related interventional trials (471 in ChiCTR and






Clinicaltrials.gov (USA) 1561(0.5) 339,863
Chinese Clinical Trial Registry (ChiCTR) 648 (2.0) 32,553
EU Clinical Trials Register (EU-CTR) 196 (0.5) 37,185
Iranian Registry of Clinical Trials (IRCT) 195 (0.8) 24,573
Clinical Trials Registry—India (CTRI) 99 (7.0) 1475
German Clinical Trials Register (DRKS) 67 (1.7) 3959
Japan Primary Registries Network (JPRN) 64 (0.2) 28,794
Australian New Zealand Clinical Trials Registry
(ANZCTR)
52 (0.2) 27,187
The Netherlands National Trial Register (NTR) 52 (0.6) 8613
International Standard Randomized Control Number
(ISRCTN)
35 (0.4) 11,381
Brazilian Clinical Trials Registry (ReBec) 10 (0.2) 4085
Pan African Clinical Trial Registry (PACTR) 6 (0.5) 1162
Clinical Research Information Service (CRiS), Republic of
Korea
2 (0.4) 505
Lebanese Clinical Trials Registry (LBCTR) 2 (3.0) 71
Peruvian Clinical Trial Registry (REPEC) 0 (0.0) 1849
Sri Lanka Clinical Trials Registry (SLCTR) 1 (0.3) 349
Thai Clinical Trials Registry (TCTR) 9 (3.0) 336
Cuban Public Registry of Clinical Trials(RPCEC) 19 (NA) NA
https://doi.org/10.1371/journal.pone.0240123.t002
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143 in ClinicalTrials.gov) [33]. The rise may be linked to the breakthrough news from China
and other countries that announced a successful drug treatment [34]. In retrospect, however,
the announcement by Chinese scientists that made claims for chloroquine was not a true
breakthrough in COVID-19 treatment; nonetheless, it could have attracted low-quality
research and clinical practice [17, 35, 36].
Many of the systematic review protocols registered in PROSPERO (n = 962) are focused on
treatment; however, they may encounter limitations due to the scarcity of the number or of the
quality of clinical trials [17]. The secondary literature can be supported by indirect evidence
from primary studies involving patients different from those of interest (i.e., COVID-19), as
suggested by the Grading of Recommendations Assessment, Development and Evaluation
Table 3. Characteristics of primary registries with highest number of COVID-19-related trials. (absolute frequencies).
Characteristic Clinicaltrials.gov N = 1621
no. (%)
Chinese Clinical Trial Registry (ChiCTR)
N = 652 no. (%)
EU Clinical Trials Register N = 196
no. (%)
Country Africa 56 (3.5) - -
Central America 3 (0.2) - -
East Asia (China) 120 (7.4) 652 (100.0) -
Japan 4 (0.2) - -
Europe 628 (38.7) - 196 (100.0)
Middle east 83 (5.1) - -
North America 380 (23.4) - -
Canada 44 (2.7) - -
United States 326 (20.1) - -
Mexico 18 (1.1) - -
North Asia 13 (0.8) - -
Pacifica 10 (0.6) - -
South America 48 (2.9) - -
South Asia 20 (1.2) - -
South-East Asia 18 (1.1) -
Study Type Interventional 940 (57.9) 323 (49.5) -
Observational 663 (40.9) 260 (39.9) -
Other (i.e., patient
registries)
125 (7.7) 69 (10.6) -
Phase Early Phase 1 19 (1.2) 218� (33.4) -
Phase 1 91 (5.6) 13 (2.0) 6 (3.1)
Phase 2 375 (23.1) 8�� (1.2) 99 (50.5)
Phase 3 241 (14.9) 3���(0.5) 75 (38.3)
Phase 4 55 (3.4) 67 (10.3) 33 (16.8)
Not applicable 282 (17.4) 212 (32.5) -
Recruiting
status
Recruiting 795 (49.0) 308 (47.2) 194 (98.9)
Complete 76 (4.7) 53 (8.1) 0
Suspended/temporarily
halted
7 (0.4) 16 (2.5) 0
Other (e.g. withdrawn) 8 (0.5) 275 (42.2) 1 (0.5)
Na�: records not available because not possible to retrieve.
Data were collected as reported in primary registers.
� phase 0 for ChiCTR.
��3 trials were phase I-II.
���1 trial was phase II-III.
https://doi.org/10.1371/journal.pone.0240123.t003
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(GRADE) approach [37]. The search for answers, treatments, and vaccines during a pandemic
ought to be based on the highest levels of evidence such as systematic reviews and randomized
controlled trials. Furthermore, companies and universities have begun to accelerate the discov-
ery of experimental drugs and vaccines for COVID-19 through their research and develop-
ment pipeline [38]. The World Health Organization (WHO)’s Blueprint list recognizes
coronaviruses as infectious agents of priority importance: given the public health emergencies
of international concern and the current absence of efficacious drugs and vaccines, research
and development need to be accelerated if diseases caused by coronaviruses are to be con-
trolled [39].
For the duration of the COVID-19 pandemic, several scientific journals allow access to pub-
lications through preprints posted online [40–42]. However, the credibility of preprints not
published in a reputable peer-reviewed journal is uncertain. We found that only 8% of pre-
prints were published in academic journals after undergoing peer review. We wonder whether
time constraints on converting preprints into a final peer-reviewed version and then waiting
for publication are the reasons for such a low percentage. The time to publication of a defini-
tive manuscript can take up to 166 days for a preprint to be published with its DOI in a journal
article [43]. One fourth of the published preprints we retrieved took between 52 and 117 days
to appear in an academic journal. Publication setbacks, often due to bottlenecks in the peer-
review process, can delay the timely dissemination of information in a global health emergency
like the present COVID-19 pandemic [43]. Furthermore, unpublished studies generate a waste
of effort and money invested in health and medical research globally [44, 45]. We noted that
findings in areas like mathematics were published only on preprint servers like ArXiv [46, 47].
The potential harm from posting erroneous provisional research is one reason why the medi-
cal community was so cautious about preprints in the first place [48]. But it is interesting to
observe that preprints are now gaining more attention and citations than the corresponding
peer-reviewed article (i.e., academic publication) [49]. While it is still soon to analyze citation
trends for COVID-19-related articles, the publication trends we observed (as of 20 May 2020)
were remarkable for the greater number of preprints than academic publications and the





Species Humans 959 99.0
Animals 3 0.3




Health impacts 160 17.0
Mental health 76 8.0
Other 31 3.0
Personnel protective equipment 17 2.0
Prognosis 50 5.0
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higher percentage of empirical research reported in preprints. This observation contrasts with
the findings by Lv et al. (as of 6 February 2020) who reported that academic journal articles
accounted for 77.1% of study publications, preprints for 14.1%, while 8% were published only
online [50]. A plausible explanation for these discrepancies is the sheer amount of recent
empirical studies more rapidly accessible in preprint databases than in academic journals.
Preprints provide a faster and iterative alternative or complement to journal publication
and the peer-review system. In addition, they catalyze biomedical discovery, support career
advancement, and improve scientific communication [43]. If all scientific publishers endorsed
preprint posting for research, it would serve as a preliminary step to publication and a clear
signal to all scientists that preprints are an integral part of scientific communication [21]. In
essence, better utilization of preprints would mean better fruition of trusted science. By track-
ing the preprint along the publication process the reliability of research can be controlled and
differentiated from the final peer-reviewed publication. Also, it might also benefit the author
and the scientific community alike: the former can share their research and attract immediate
attention, while the latter can directly access the research paper, give feedback to improve the
manuscript, and open a discussion leading to new ideas, follow-up studies or collaboration
with other research groups [51]. This may be viewed as a necessary step toward a more open
and transparent peer-review process, which forms the cornerstone of scientific activities and
part of a system that ensures that only quality research papers are released into the scientific
community [23]. Commentaries, letters to the editor, and other forms of non-research publi-
cations were largely found in academic journals. Though less suitable as preprints, they can
still benefit from external peer-review since they are biased or present personal perspectives.
Informed readers of empirical research can more objectively appraise the research methods,
the data presented, the validity of its conclusions or limitations in either preprint or definitive
versions.
The challenge in this emergency is to increase the amount of completed and published
research and translate it into practice. However, a recent commentary in International Immu-
nopharmacology stated, “quantity does not equal quality” [52]. While the dissemination of data
is an essential part of the response, the detection of poor methodology and the retraction of
clinical trials published in reputable journals are unfortunate examples of misconduct and
rushed research in this pandemic [17, 53].
Limitations of the study
This study covers only journals and publications indexed in PubMed, a comprehensive but
not exhaustive database for biomedical literature. We searched only a few of the repositories
and servers for posting preprints (i.e., bioRxiv and medRxiv). We used the COVID-19 section
of these servers to investigate the preprint versions at the time of our data extraction. We col-
lected data within a tightly defined window (December 2019 through May 2020). Since no fil-
ter nor topics exist for selecting preprint categories and the average time the servers take to
display search results can be long [54], we performed hand screenings. This partly reduces the
validity of the comparison of study types (academic vs. preprint). An illustrative example is
that of the epidemiologic studies: we retrieved different study types in preprints (e.g., case-con-
trol studies, cross-sectional studies, biological and mathematical models), whereas when
searching PubMed we used MeSH terms such as clustered study design (e.g., case-control
studies, cross-sectional studies). In addition, epidemiological studies are not indexed in
PubMed as a “publication type” like RCTs, for instance. This can affect the reliability, accuracy,
and speed of indexation of epidemiological studies in PubMed. compared to preprint servers.
It may also explain why many studies retrieved from PubMed were not yet classified by study
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type (the total sum of the articles indexed by study type was clearly below the total number of
papers retrieved). Therefore, clear-cut publication types like RCTs or letters to the editors may
have had faster, more reliable indexation. It is reasonable to infer that many of the studies
without indexation for a publication or study type could be some format other than an RCT or
commentaries/letters (e.g., epidemiologic, secondary data analysis, etc.). Although indexation
of COVID-19-related research has been prioritized, delays may apply and these may have been
visible in the data we obtained during the weeks of May 2020.
When needed (when the search filters or tags could not be reliably applied), one researcher
performed manual coding and the other verified it rather than involving two independent
researchers. This option is typical of rapid review types and a compromise to expedite the
results for which timeliness is key, perhaps at the expense of a certain degree of uncertainty
about the accuracy of the results. We did not adjust the characteristics for a country’s popula-
tion size, for example using the World Bank’s data to facilitate comparison of the number of
studies per country (https://data.worldbank.org/).
Conclusion
The number of COVID-19-related publications has increased dramatically since the outbreak
began in late 2019. The bulk of the scientific literature in the first five months of the epidemic
comprised short reports of data, opinions or perspectives (e.g., letters to the editor or commen-
taries) or reported (secondary) data rather than primary data. Numerous clinical trials and sys-
tematic reviews are registered but their results have not yet been published. The focus of
research is effective preventive/control and therapeutic strategies, reflecting the initial response
by the research community. Preprints can provide readers with direct, rapid access to research
findings. Despite the deluge of papers [55], screening and reviewing preprints might benefit
both the authors and the scientific community, while informing the general public with timely
access to scientific content and discussions that could boost scientific credibility [41].
In brief, we noted a huge increase in the amount of scientific papers within a short period
of time: COVID-19 has aroused an unprecedented interest in research, a demand for answers,
and rapid publication of findings. Nevertheless, efforts and time should be devoted to scientifi-
cally sound information rather than rushing to publish results that may not be fit to print. Over-
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